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Abstract 
UCH-L1 is a member of the ubiquitin C-terminal hydrolase (UCH) family of 
proteins that is expressed predominantly in neuronal tissues. Previous studies have 
shown that UCH-L1 is highly expressed in different types of cancers, suggesting a 
role in tumorigenesis. Currently, it is not clear how UCH-L1 activity is regulated in 
vivo. We hypothesized that enzymatic catalysis of UCH-L1 may allosterically be 
regulated by interacting proteins. A screen to identify UCH-L1 interacting protein 
revealed that JAB1/CSN-5, a COP-9 signalosome (CSN) subunit, to be the UCH-L1 
interacting protein. The present study is aimed at understanding the role of Jab1 
interaction on UCH-L1 activity. Jab1 is known to alter the activity of the other 
interacting protein either by phosphorylation or promote degradation by ubiquitin 
proteasome pathway. We performed UCHL1 activity assay on Ubiquitin substrate 
having C-terminal peptide extension and found that the presence of JAB1 in the 
assay is completely inhibiting UCHL1 deubiquitinase activity, without 
phosphorylation or ubiquitylation. Our results indicate a novel mode of regulation of 
UCHL1 activity by physical interaction with Jab1. The results from the present 
study will be helpful for further understanding of regulation of UCHL1 activity. It 
would also be of interest to see if similar mechanism exists for other UCH family 
and also will explore substrate specificity, stability and posttranslational 
modification of UCH-L1 in presence of Jab1. The outcome of this study may 
facilitate the design of drugs to treat cancers where UCH-L1 is overexpressed. 
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Nomenclature: 
 
 
 
1. aa                                 amino acid. 
2. APS              Ammonium per sulfate  
3. Amp              Ampicillin 
4. AP-1                            Activator protein1 
5. β-ME                         Beta merceptoethanol 
6. bp                                base pair 
7. °C                                Degree Celsius. 
8. Cdna                            Complementary dna 
9. COP                            Constitutive photo morphogenesis  
10. CSN                            COP9 signallosome 
11. DNA                           Deoxyribonucleic acid 
12. DTT                            Dithiothretol 
13. DUB                           Deubiquitinase 
14. E.Coli                          Escherichia coli 
15. et.al                              and other 
16. EDTA                          Ethylene Di amino tetra acetic acid 
17. g                                   gram or gravity depending on context 
18. HF                                High fidelity 
19. His                                Histidine 
20. IPTG                          Isopropyl thio galactopyranosidase 
21. JAB1                            Jun activation domain binding protein1 
22. JAMM                         JAB1/MPN/Mov34 metalloenzyme 
23. JNK                              c-jun N-terminal kinase 
24. kb                                  kilo base pair 
25. kD                                 kilo dalton 
26. LB               Luria Bertani. 
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27. M                                    Molar 
28. mg                                  milligram 
29. min                                 minute 
30. ml                                    milliliter 
31. Mw                                 molecular wt 
32. n                                      nano 
33. NCBI                              National centre for Biotechnology 
34. Ni-NTA                 Nickel Nitrilo tri acetic acid 
35. PAGE                            Polyacrylamide gel electrophoresis 
36. PCR                            Polymerase chain Reaction 
37. pH                                   -log10(H+) 
38. RNAase                          Ribonuclease 
39. RT                                   Room temperature 
40. sec                                   Second 
41. SDS                             Sodium do decyl sulphate 
42. SOC                             Super optimal broth with catabolic repression 
43. TE                             Tris EDTA 
44. TEMED      Tetra methyl ethylene di amine 
45. TAE                 Tris base, Acetic Acid, EDTA 
46. Tris / THAM                Tris hydroxyl methyl amino methane 
47. TB                 Tariffic Broth 
48. Ub                                  Ubiquitin 
49. UCH                 Ubiquitin C-terminal Hydrolase. 
50. UCH-L1                        Ubiquitin C-terminal hydrolase- 1 
51. UCHL-3                        Ubiquitin C-terminal hydrolase- 3 
52. UPS                               Ubiquitin proteasome system 
53. USP                               Ubiquitin specific proteases 
54. USP15                           Ubiquitin specific protease 15 
55. U.V                                Ultra violet 
56. v/v                                 volume in volume 
57. w/v                                weight in volume 
58. μ                                    micro 
 viii 
59. μg                                  micro gram 
60. μl                                   micro liter 
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Introduction                                                Chapter 1 
1.1. Ubiquitin 
Ubiquitin (Ub) is a highly conserved small (76 amino acid) eukaryotic protein 
that is covalently attached to proteins via its carboxy terminal glycine residue by 
the consecutive actions of three distinct enzymes. Ub is first activated by the Ub-
activating enzyme (E1), transferred to a Ub-conjugating enzyme (E2), and then 
attached to a target protein under the control of a Ub ligase (E3). There are only a 
few E1 enzymes, ~ 30 E2s, and over 600 E3s in humans, which together generate 
a variety of different ubiquitinated forms of many thousands of proteins by 
monoubiquitination as well as by polyubiquitinations [51].Importantly, ubiquitin 
itself has seven lysine residues, all of which can act as acceptors for further 
ubiquitination generating polyubiquitin chains. Lys 48-linked (K48) polyubiquitin 
targets substrate proteins for proteasomal degradation whereas most non-
proteolytic functions of ubiquitin chains are currently associated with Lys 63-
linked (K63) ubiquitin polymers. A variety of ubiquitinated products are then 
specifically recognized either by Ub receptors containing Ub-binding domains 
(UBD), leading to downstream effects, or by deubiquitinating enzymes (DUBs), 
which catalyze the reverse reaction. Thus, the Ub system is extremely versatile 
and can play multiple essential roles in various cellular processes by regulating 
not only protein stability but also protein interactions, trafficking, and activation. 
1.2. UCH-L1, a deubiquitinating enzyme: Protein ubiquitination, like protein 
phosphorylation, is a reversible process. Deubiquitinating enzymes (DUBs), 
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which belong to the superfamily of cysteine proteases, remove Ub from protein 
substrates. DUBs are grouped into two subfamilies: the ubiquitin C-terminal 
hydrolases (UCHs) and the ubiquitin-specific proteases (USPs/UBPs). In general, 
UCHs catalyze hydrolysis of C-terminal peptide bond and USPs/UBPs hydrolyse 
isopeptide bond between the K48 and K63 linked polyubiquitin chains [20]. To 
date, four members have been known in UCH family in human: UCH-L1, UCH-
L2 (also known as BRCA1-associated protein-1 or BAP1), UCH-L3, UCH-L5 
(UCH37). All the UCH family members have a conserved catalytic domain 
consisting of about 230 amino acids. The crystal structures of UCH-L1, UCH-L3 
and UCH-L5 have been solved [11, 16, 32], showing that the UCH-domain 
contains three conserved residues, cysteine, histidine and aspartate. The UCH 
enzymes prefer to cleave relatively small protein substrates from the C-terminus 
of Ub, and the size limit is imposed by a loop that partially occludes the active 
site of these enzymes [20]. 
 Ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1, aka PGP9.5) is an 
abundant neuronal protein consisting of 223 amino acids [53]. UCH-L1 is an 
abundant neuronal protein, comprising approximately 2% of total brain protein 
[54]. Although low levels of UCH-L1 protein was reported to be present in 
kidneys, breast epithelium, and reproductive tissues, UCH-L1 was absent in most 
other tissues [5]. Mice lacking functional UCH-L1 developed gracile axonal 
dystrophy, a recessive neurodegenerative disease [35, 36]. At the subcellular 
level, UCH-L1 was primarily found in the cytoplasm, but recent reports indicate 
that a subpopulation of UCH-L1 can be transiently localized to the nucleus[4, 24]. 
In vitro biochemical studies revealed that UCH-L1 hydrolyzes Ub after its C-
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terminal glycine residue to generate monomeric Ub and that this activity was 
dependent upon the catalytic residues C90 and H161 [19]. Analysis of UCH-L1 
crystal structure revealed that the catalytic residues were not accessible to large 
polymers of Ub and suggested that UCH-L1 and could accommodate small 
adducts of Ub [27]. It is possible that substrate binding and/or the presence of 
interacting proteins may induce a conformational change, allowing UCH-L1 to 
process larger Ub chains. However, this has not yet been demonstrated in vitro or 
in vivo.  
1.3. UCH-L1 function: Although the exact cellular function of UCH-L1 is not 
fully understood, several studies suggest that UCH-L1 regulates the cellular pool 
of free Ub. In most organisms, Ub is expressed as a linear polymer, pro-ubiquitin, 
consisting of multiple copies of Ub and one or more amino acids appended to the 
C-terminus of the final Ub. For example, in humans polyubiquitin-C (UbC) is 
expressed as 9 Ub monomers followed by a Val and polyubiquitin-B (UbB) as 3 
monomers followed by a Cys [52]. UCH-L1 was reported to cleave the Ub gene 
products UbB and UbC and the ribosomal ubiquitin fusion protein UbA80 to 
generate monomeric Ub when co-expressed in E. coli [20]. In contrast to other 
DUBs, in vitro studies revealed that UCH-L1 could not directly catalyze the 
deubiquitination of ubiquitinated protein substrates [20]. Moreover, no in vivo 
UCH-L1 substrates have been identified thus far.   
 UCH-L1 and UCH-L3 are composed entirely of the UCH domain and are 
capable of cleaving amino acids linked by peptide bonds to the C-terminus of Ub, 
yet they are inactive towards di-Ub. In contrast, BAP1 and UCH37 are capable of 
acting on di-Ub and poly-Ub chains. The basis of this specificity stems from a 
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loop that crosses over the UCH catalytic site, forming a pore through which the 
C-terminus of Ub must be threaded. The most striking structural feature relating 
to substrate specificity is presence of this loop in UCH-L1 and UCH-L3. There 
are two models explaining function of this loop. In one scenario substrates would 
enter the active site cleft by passing underneath the arch created by the active site 
crossover loop. This model would readily explain the ability of UCHs to 
hydrolyze small Ub C-terminal extensions, as the loop itself would likely impose 
significant size restrictions on potential substrates. However, the recent reports of 
larger substrates hydrolyzed by UCH enzymes conflict with the model of 
substrate threading through the crossover loop. The maximum theoretical internal 
diameter of the active site crossover loop is ~12–15 Å. Polyubiquitinated 
substrates would be impossible to accommodate underneath this loop. The 
alternate model for UCH hydrolysis was thus required to account fully for the 
observed action of these enzymes. According to this model, to accommodate 
larger substrates in the active site of UCHs one must relieve steric constraints by 
peeling away the active site crossover loop from the active site cleft. Besides 
proteolysis, UCH-L1 was also reported to bind free Ub monomers and prevented 
its lysosomal degradation [33]. Association of UCH-L1 with monomeric Ub 
occured independently of the catalytic C90 residue, indicating that mono-Ub 
binding did not depend upon UCH-L1 hydrolase activity [33]. The role of UCH-
L1 in the regulation of the free Ub pool was also supported by the observation 
that levels of monomeric Ub were decreased in gracile axonal dystrophy (gad) 
mice, which lacked functional UCH-L1 [33]. Although the best understood 
function of UCH-L1 is maintenance of cellular pool of free Ub, UCH-L1 was 
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reported to possess putative, dimerization-dependent E3 ligase activity in addition 
to its hydrolase function. In vitro experiments showed that dimeric UCH-L1 
promoted K63-linked polyubiquitination of α-synculein [23]. Unlike other E3 
ligases, UCH-L1 E3 ligase activity was observed in the absence of ATP, which 
was different from the mechanism of conventional ubiquitination. It is currently 
not known whether UCH-L1 exhibits E3 ligase activity in vivo. Further 
investigation into UCH-L1 enzymatic function is needed to understand its role in 
health and disease. Recently, a post-translational modification of UCH-L1 that 
controls the function of UCH-L1 has been identified [26]. It was observed that 
UCH-L1 was monoubiquitylated on a lysine residue near the active site (K157). 
This modification restricted ubiquitin binding. However, UCH-L1 
deubiquitination activity removed this Ub and prevented permanent mono-
ubiquitination.  
1.4. UCH-L1 and cancer: Although the expression of UCH-L1 is limited to 
neuronal tissue [53], UCH-L1 levels were found to be increased in various types 
of malignancies including acute lymphoblastic leukemia, breast cancer, leukemia, 
medullary thyroid carcinoma, non-small cell lung cancer; neuroblastoma, 
prostate, esophageal, colorectal and pancreatic cancer indicating the involvement 
of UCHL1 as oncogene in the pathogenesis of these tumors [14, 21, 28, 29, 34, 
38, 44, 45, 56, 57]. Overexpression of UCH-L3 and UCH-L5 were reported in 
breast cancer and cervical carcinoma [28, 40] and UCH-L2/BAP1 overexpression 
was found to be associated with lung and breast cancer [9, 15].Contrary to 
previous reports proposing cancer-promoting role of UCH-L1, recent studies 
revealed that UCH-L1 attenuated tumor growth and maturation in prostate cancer 
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and breast cancer [48, 49]16, 52]. In contrast to previous studies demonstrating 
that UCH-L1 is upregulated in breast tumors, UCH-L1 mRNA expression was 
reported to be decreased in several breast carcinoma cell lines [55]. Therefore it is 
clear that although there has been growing evidence on the relation between UCH 
enzymes and oncogenesis, its role in carcinogenesis is still unknown. Elevated Ub 
level is essential for the survival and proliferation of the cancer cells; but not for 
the viability of normal cells. Thus, the down regulation of Ub levels would be 
preferentially detrimental to cancer cells. Cancer cells acquire their malignant 
capabilities through variuos mutations and extensively reprogrammed pathways, 
which inevitably generate a variety of stresses, including proteotoxic stress [13]. 
Cancer cells must tolerate these increased stresses through the activity of Ub-
proteasomal system by degrading unnatural proteins and thus considered 
attractive cancer therapeutic targets [25, 41]. Therefore, the suppression of the Ub 
level, for example by UCH-L1 inactivation, may lead to stress sensitization by 
weakening the stress-supporting system. 
1.5. UCH-L1 interacting protein-Jab1: Using UCH-L1 as bait in a yeast 2-
hybrid assay with an expression cDNA library derived from fetal brain, it was 
shown to interact with JAB1 (Jun activation domain-binding protein 1) [6]. The 
study also confirmed that the two proteins interact in vivo via co-
immunoprecipitation. Other proteins that are known to interact with UCH-L1 are 
UBC9 and Ran binding protein (RanBP). 
1.6. Jab1/CSN5 function: The COP9 signalosome (CSN) complex is composed 
of 8 subunits (CSN1-8) and well conserved in all eukaryotes from yeast to 
humans and involved in various biological responses. CSN function was orginally 
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discovered in Arabidopsis. In the absence of light signals, the CSN represses 
photomorphogenesis through the degradation of the HY5 transcription factor. 
Mutations in the CSN lead to constitutive photomorphogenesis (cop) in the dark. 
Among the 8 components of the CSN, the fifth subunit of the CSN (CSN5, also 
known as Jab1) is unique in many ways. Mammalian CSN5 was originally 
identified as a protein binding to the transcription factors c-Jun, a member of AP-
1 transcription factors family, and so termed as Jun-activation-domain-binding 
protein-1 (Jab1). AP-1 (activating protein-I) is a collective term referring to 
dimeric transcription factors composed of Jun, Fos or ATF (activating 
transcription factor) subunits that bind to a common DNA site, the AP-l-binding 
site. Jab1 determines the specificity of AP-1 transcription factors. The AP-1 
complex can respond immediately to many different extracellular stimuli, 
epidermal growth factor (EGF), and serum. Although c-Jun and c-Fos have very 
similar DNA binding and dimerization domains, they seem to activate distinct 
sets of target genes [33-35]. Jab1/CSN5 specifically stabilized the protein-DNA 
complexes of c-Jun and Jun-D with its cognate AP-1 DNA binding sites. 
Jab1/CSN5 involvement as a specificity factor was demonstrated for a number of 
proteins in addition to c-Jun. Jab1/CSN5 is a transcriptional coactivator and 
potential specificity factor for E2F-1, IB, p105, NFκB and p53 [2, 8, 12, 39], yet 
the mechanism by which it acts is poorly defined. Phosphorylation is one 
mechanism of regulation that could be attributed to Jab1/CSN5-associated kinase. 
In case of p53, CSN-specific phosphorylation of Thr155 was an important 
prerequisite for degradation of the tumor suppressor by the Ub–26S proteasome 
system [2]. Inhibition of the CSN-associated kinase by curcumin or a competitor 
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peptide derived from p53 resulted in the accumulation of endogenous p53. CSN 
phosphorylated c-Jun at the N-terminal transactivation domain including Ser63 
and Ser73, which prevented ubiquitylation and degradation of the transcription 
factor [30].  Jab1 also controls the nuclear export and 26S proteasome-
dependent degradation of several nuclear proteins, such as cyclin-dependent 
kinase inhibitor p27
Kip1
, LHR, Smad, estrogen receptor, topoisomerase II and p53 
[2, 3, 7, 17, 22, 46, 50, 58]. It was shown that CSN-unassociated free form of 
Jab1/CSN5 interacted with and promoted the export of p27
Kip1
 from the nucleus 
to the cytoplasm and enhances its degradation by a proteasome [46].  However, 
the relationship between Jab1 and the 26S proteasome complex during protein 
degradation is not clearly understood. It was recently reported that in cooperation 
with CSN, Jab1 mediates the deneddylation of the cullin component of SCF 
ubiquitin-protein isopeptide ligase, which may promote cullin-dependent 
proteolysis (24). 
1.7 Jab1 interaction domain: Small domain containing conserved Asp and Leu 
residues was discovered within the Jab1/CSN5 interacting region of p27
kip
. 
Sequence analysis revealed that this domain was present in other Jab1 interacting 
proteins like c-Jun, LFA1, suggesting an essential role in interaction with 
Jab1/CSN5 [47].  
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Objective                                                         Chapter 2 
Significance of Jab1-UCH-L1 interaction is not known. Jab1 is known to alter the 
protein function by phosphorylation, promoting degradation or introducing 
conformational change [8, 10, 31]. UCH-L1 crystal structure revealed that the 
catalytic site was not accessible to large polymers of Ub. However, in an apparent 
contradiction to these results, UCH-L1 was also reported to be involved in 
deubiquitination of number of cellular proteins (Introduction section, page 4). 
Apart from the exact in vivo function and substrate of UCH-L1 almost nothing is 
known about the regulation of UCH-L1 inside the cell. Therefore studying Jab1-
UCH-L1 interaction might help us in understanding cellular function or regulation 
of UCH-L1. 
 
Objective: Effect of Jab1 interaction on UCH-L1 activity. 
Specific aim-I: Cloning, expression, purification of recombinant UCH-L. 
Specific aim-II: Site-directed mutagenesis of UCH-L1 to generate C90A   active 
site mutant and purification of recombinant C90A UCH-L1.  
Specific aim-III: Cloning, expression, purification of recombinant Ubiquitin. 
Specific aim-IV: In vitro assay of UCH-L1 with C90A UCH-L1 as control. 
Specific aim-V: Cloning, expression, purification of recombinant Jab1.          
Specific aim -VI: In vitro assay of UCH-L1 in presence of recombinant Jab1. 
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Materials and methods                            Chapter   3 
 
3.  Molecular biology methods: 
3.1. Primers used for PCR: Primers were designed based on cDNA sequences of 
genes (taken from NCBI http://www.ncbi.nlm.nih.gov/nucleotide). Suitable 
restriction enzymes sites were added to 5’ends of each primer to promote 
directional cloning. A NEB tool (http://tools.neb.com/NEBcutter2/index.php) was 
used to select appropriate restriction enzymes. Stuffer sequences of 4-5 
nucleotides were also inserted in primers flanking the restriction sites at the ends, 
which facilitate binding of restriction enzymes to their respective sites. 
Chemically synthesized oligonucleotides (Imperial Life Sciences) were dissolved 
in molecular grade water by vigorous vortexing to a final concentration of 100μM 
and stored at -20°C. 
Table 1: Oligonucleotide primers used in study. 
Gene Name of the Primer Sequence (5'-3') 
UCHL1 UCHL1-BamHI-Sen CCTGGGATCCATGCAGCTCAAGCCGATGGAGAT CAA CCCC 
UCHL1-SalI-HindIII-Anti AAAAGTCGACAAGCTTTTAGGCTGCCTTGCAGAGAG 
CCACGG C 
Ubiquitin Ub-NdeI-Sen     GATATACATATGCAGATCTTCGTGAAGACTCTGACTGG  
Ub-HindIII-Anti GCCTAGAAGCTTCTAGCAATGATGATGATGATGATGCTT 
CCCACCTCTGAGACGGAGTACC. 
JAB1 JAB1-BamHI-Sen AGTCGGATCCATGGCGGCGTCCGGGAGCG 
JAB1-SalI-Anti GCGCGTCGACTTAAGAGATGTTAATTTGATTAAAC  
 
3.2 .Polymerase chain reaction: To amplify specific DNA sequence PCR was 
done using primers. Phusion DNA polymerase enzyme (New England Biolabs, 
Cat.no M0530S) was used in all the PCR reactions. Composition and reagents 
used for standard PCR reaction mixture of 50μl is given below in Table 2. 
Templates used in the PCR reaction were of high quality, supercoiled plasmid or 
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cDNA. The volume of template DNA was diffrerent for different target 
amplification; for example, for amplifying UCHL1, 1l of pGEFPC3-hUCHL1 
was used as template; for amplifying Jab1, 1l of human cDNA was used as 
template; for amplifying Ubiquitin, 0.5l of pET-21b was used as template. All 
components were thawed and mixed properly prior to use, in the following 
order,10x  buffer was first diluted with nuclease free water and the dNTPs were 
added. Template and then primers were added sequentially. Finally, just before 
starting the reaction Phusion DNA polymerase was added. Reactions were set up 
on ice in 0.2ml PCR tubes (Axygen, Cat. No: PCR-02-C). All components were 
mixed together by finger tapping followed by short centrifugation (5000rpm, 
2min, RT). Thermal cycling condition for routine PCR performed is given in 
Table 3. PCRs were performed in Veriti 96 well thermal cycler from Applied 
Biosystems (model no.9902). After completion of the PCR, amplified DNA was 
analyzed by electrophoresis on agarose gel as described in section 3.3. 
Table 2.Composition of PCR reaction mixture.  
Components Volume used (in μl)        Final conc.        
HF Phusion buffer (5x) 10μl  1X 
dNTP  10mM  0.5μl 
Template DNA As mentioned 
above 
1μg 
Forward and Reverse 
primers 
0.25μl                 200nm 
Phusion DNA Polymerase 1.0μl  2U 
 
 12 
Table 3. Thermal cycling condition for PCR 
For UCHL1 amplification: 
Steps       Temperature Time     
Initial denaturation   98°C 30 sec 
   
  32 cycles 
  98°C 10 sec 
 57°C 30 sec 
 72°C 1 min 
Final Extension  72°C 10min 
 
Ubiquitin amplification: 
Steps       Temperature Time     
Initial denaturation   98°C  30 sec 
   
      32 cycles 
  98°C  10 sec 
 57°C  30 sec 
 72°C 1:30 min 
Final Extension  72°C 10min 
 
For JAB1 amplification: 
Steps       Temprature Time     
Initial denaturation   98°C 30 sec 
  
   32 cycles 
  98°C 10 sec 
57°C 30 sec 
72°C 1 min 
Final Extension 72°C 10min 
13 
 
3.3. Agarose gel electrophoresis: Horizontal agarose gel (0.8-1.0%) 
electrophoresis were routinely performed to separate DNA frangments of various 
lengths (ranging from 100bp-10kb). Appropriate amount of agarose 
(SeaKem®LE, LONZA, Cat. no. 50005) was dissolved in 1X TAE buffer (40mM 
Tris-acetate; 1mM EDTA pH 8.0) by heating in microwave oven. After cooling, 
Ethidium bromide was added of concentration 1μg/ml into the gel solution and 
then poured into gel a mould and a comb was inserted to generate wells. After 30-
45 minutes, when the gel got solidified completely, comb was removed gently 
and gel mounted into electrophoresis chamber containing 1X TAE (40mM Tris-
acetate; 1mM EDTA pH 8.0). DNA samples and size marker were mixed with 
appropriate volume of 1X DNA loading dye (6x stock: 0.25% bromophenol blue; 
0.25 xylene cyanol FF; 30% v/v glycerol,(Cat.no:R0611, Thermo scientific). 
Electrophoresis were generally carried out at 80 volt till the xylene cynol dye 
migrated to distance of half of the gel.DNA bands were visualized in gene 
documentation system from SynGene (Model no: Chemi XR5, S.No 
DR4V2/2355). DNA ladder of either 100kb (catalog no: SM0241, Thermo 
scientific) for ubiquitin and 1kb ladeer (Cat no: SM0311 Thermo scientific) for 
JAB1and UCHL1, linearized plasmid DNA were used, respectively, for fragment 
size determination.   
3.4. PCR Clean up: Before using in further experiments, PCR amplified DNA 
fragments were cleaned to remove the traces of dNTPs, enzyme, residual primers 
etc. Gene jet PCR clean Up kit (Thermo scientific, Cat.no K0691) was used for 
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this purpose to get pure amplified DNA free from contaminants. The process was 
carried out according to manufacturer's instructions. 
3.5. Restriction Digestion and gel extraction of DNA: Restriction 
endonucleases were used to promote directional cloning. All the restriction 
enzymes were purchased from New England Biolabs. For cloning Ubiquitin, 
double digestion of the pRSETA vector and the PCR DNA were performed using 
NEB buffer 4, which is compatible for both enzymes. Cloning was successful 
when 34μl (71.2ng/μl) of PCR DNA was digested with BamH1 and NdeI for 6 
hours and pRSETA vector was digested with BamH1 and NdeI for 16 hours. 
Digested products were first checked on 0.8% agarose gel for completion of 
digestion. For cloning UCHL1, double digestion of the pRSETA vector and the 
PCR DNA were performed using NEB buffer 4, which is compatible for both 
enzymes. Cloning was successful when 34μl of (46.6)ng/μl of PCR DNA was 
digested with BamH1 and HINDIII for 6h at 37°C incubation and pRSETA vector 
was digested with BamH1 and HINDIII for overnight digestion at 37°C. For 
cloning JAB1, double digestion of the pGEX6P1 vector and the JAB1 PCR DNA 
were performed using NEB buffer 4, which is compatible for both enzymes. 
Cloning was successful when 34μl of (187.7ng/μl) of PCR DNA was digested 
with BamH1 and SalI for 6 hours and pGEX6P vector was digested with BamHI 
and SalI for 16 hours. Digested products were first checked on 0.8% agarose gel 
for completion of digestion. In order to perform gel elution of the desired band, 
agarose gel electrophoresis were carried out for restriction digested PCR DNA 
and vector DNA on 0.8% agarose gel as described earlier. Gels were visualized 
under U.V light (345nm) in a trans-illuminator. DNA bands were carefully 
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excised with a sterilized scalpel and placed into a pre-weighed of 2ml micro 
centrifuge tube and record the gel weight. DNA was extracted by using Gene Jet 
Gel Extraction kit (Thermo scientific, Cat.no K0691), following manufacturers 
protocol. 
3.6. Ligation Reaction: Ligation reactions were performed using T4-DNA ligase 
(New England Biolabs, Cat. no: M0202S).. For cloning UCH-L1, in total reaction 
volume of 10μl contained 1μl of restriction digested and gel extracted vector 
(28.5ng), 7μl of restriction digested and gel extracted PCR DNA (81.5ng) ,1μl 
(400U) of T4-DNA ligase and 1μl of ligation buffer containing ATP. Ligation 
was performed at 16°C for 10 hours and the whole ligation reactions were used 
for transformation into E. coli (DH5α). For cloning Ubiquitin, in total reaction 
volume of 10μl contained 1μl of restriction digested and gel extracted vector 
(23.95ng), 7μl of restriction digested and gel extracted PCR DNA (58.1ng) ,1μl 
(400U) of T4-DNA ligase and 1μl of ligation buffer containing ATP. Ligation 
was performed at 16°C for 10 hours and the whole ligation reactions were used 
for transformation into E. coli (DH5α).For cloning JAB1, in total reaction volume 
of 10μl contained 1μl of restriction digested and gel extracted vector (18ng), 7μl 
of restriction digested and gel extracted PCR DNA (297.5ng) ,1μl (400U) of T4-
DNA ligase and 1μl of ligation buffer containing ATP. Ligation was performed at 
16°C for 10 hours and the whole ligation reactions were used for transformation 
into E. coli (DH5α). 
3.7. Preparation of competent E.Coli cells: Competent E. coli cells of DH5α 
and BL21 (DE3) pLysS, were prepared described by Alexander [1] by using 
MnCl2 and CaCl2. A sterilized inoculating loop was used to streak E.coli strains 
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(DH5α and BL21 (DE3) pLysS) directly from frozen glycerol stock onto an LB 
agar plate containing no antibiotic. Plate was incubated for 16 hours at 37C.A 
single colony was picked and inoculated in 5 ml of LB medium for overnight in a 
shaking incubator at 200 rpm. 1ml of this overnight grown culture was inoculated 
in a pre -warmed 100 ml of LB medium (1% tryptone, 0.5% yeast extract) 
prepared in 250ml Erlenmeyer flask. Inoculated culture was grown for 4hrs at 
30C, 100 rpm in shaking incubator under monitoring culture growth by 
measuring OD600 spectrophotometer every 20 minutes. When culture had reached 
OD600 of 0.35 it was taken out and incubated on ice for 1hr. Cells were harvested 
by centrifugation at 4000 rpm for 15 min at 4C. The supernatant was discarded 
and the cell pellet was resuspended in 12 ml of acid salt buffer-A (ASB-A, 
sodium acetate-40 mM, CaCl2-100 mM, MnCl2-70 mM, pH 5.5) and incubated on 
ice for 1 hour. The ASB treated cells were then pelleted by centrifugation carried 
out at 3500 rpm for 15 min at 4C and resuspended in 4ml of ASB-B (Sodium 
acetate-40 mM, CaCl2-100 mM, MnCl2-70 mM, 15% glycerol, pH 5.5) and were 
stored in Eppendorf tubes (aliquots of 50l) at -86 C for future use. 
3.8 Transformation of competent E. coli cells: 
(I) Transformation of competent DH5α cells: DH5α competent E.coli cells were 
prepared as described earlier. 10μl of a ligation mixture were added to 50μl 
aliquots of competent DH5 α cells and incubated on ice for 30 minutes. After that 
heat shock was given at 42°C for 30 seconds, cells were again briefly incubated 
on ice for 5 minutes and transformed competent cells were plated on LB- agar 
plates containing 100μg/ml ampicillin. Plates were incubated at 37°C overnight. 
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(II) Transformation of BL21 (DE3) pLysS competent cells: BL21 (DE3) pLysS 
competent E.coli cells were prepared as described earlier. 4μl of a plasmid DNA 
was added to 50 μl aliquots of cells and the mixture was incubated on ice for 10 
minutes. After a 42°C heat shock for 30 seconds, the cells were briefly incubated 
on ice for 5 minutes. After this incubation, entire transformation mixture was 
plated on LB-agar plates containing 100μg/ml ampicillin. Plates were incubated at 
37°C overnight for growth of cells. 
3.9. Plasmid DNA Isolation from mini bacterial culture: A single colony was 
picked out from the plate containing colonies of transformed cells and inoculated 
in 5ml of LB medium containing ampicillin. The culture was incubated in a 
shaking incubator at 37°C, 200 rpm for overnight. 2ml of this culture was used for 
isolation of plasmid DNA using Plasmid Mini-Prep kits (Fermentas Life 
Sciences, cat. no K0502) following the instructions recommended by the 
manufacturer.  
3.10. Site directed Mutagenesis: To study the enzymatic role of UCH-L1, the 
key residue (Cys90) from catalytic domain were mutated by PCR mediated site 
directed mutagenesis. Cys codon ‘TGT’ was mutated to Ala codon GCT. Primers 
were designed to create substitutions by incorporating the desired nucleotide 
changes in the center of forward primer including 19 complementary nucleotides 
on 5’ and 3’ end of the mutation. The New England Biolabs guidelines were 
followed to design the oligonucleotides, PCR protocols and transformation. The 
entire plasmid containing wild type UCH-L1 was amplified by oligonucleotides 
that carried the specific mutation. PCR specifications are as follows; 25 PCR 
cycles (with 56C annealing temperature) and 50μl total volume. PCR enzyme 
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used was Phusion High Fidelity DNA polymerase (New England Biolabs, Cat: no 
M0530S). To remove the non-mutated template plasmid, the entire PCR mixture 
was treated with 1μl of DpnI digestion at 37oC for 2h, which degrades specifically 
methylated DNA that is template plasmid purified from bacterial host. DpnI 
digested PCR mixture was then transformed to 200μl DH5α competent cells and 
grown on LB agar plates containing 100μg/ml ampicillin. After overnight 
incubation, several colonies were observed. Single colony was inoculated to 2ml 
of LB-ampicillin and plasmid was purified from grown culture as described in 
section 3.9. 
 
Table 4.  Primers used for site directed mutagenesis PCR. 
Gene Name of the 
Primer 
Sequence (5'-3') 
UCHL1 
mutagenesis 
UCHL1-C90A-Sen GCAGACCATTGGGAATTCCgctGGCACAATCGGACTTATT C 
UCHL1-SalI-HindIII-Anti 5’AAAAGTCGACAAGCTTTTAGGCTGCCTTGCAGAGAGCCA 
CGGC-3’ 
 
Protein techniques 
3.11. SDS-PAGE: Recombinant proteins were analyzed through SDS-PAGE.  
SDS-PAGE was carried using discontinuous buffer system as described by 
Laemmli (18) using Biorad gel electrophoresis apparatus (Cat. no: 165-8001). 
Throughout this study 1.5 mm thick 12% polyacrylamide (30:0.8, acrylamide to 
bisacrylamide ratio) gel containing 0.1% SDS was used for electrophoretic 
separation of proteins. For some application Biorad precast gel were also used 
(Cat. no: 456-1086). The protein samples were mixed with an equal volume of 3X 
sample buffer (2.4 ml 1M Tris-HCl pH 6.5, 3 ml 20% SDS, 3 ml 100% Glycerol, 
1.6 ml β-mercaptoethanol, 0.006 g Bromophenol blue) and heated at 100 °C for 
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10 min and were loaded into the wells of precast polyacrylamide gel.  
Electrophoresis was performed at a constant voltage of 100 or 120V by diluting 
10x buffer (Tris base 30.3g, Glycine 144g, SDS 10g in 1000ml).  After the 
electrophoresis, the gel was stained with coommasie brilliant blue (0.4% w/v 
Coomassie blue R250, 30% v/v Methanol, 10 % Acetic acid). Spectra multicolor 
broad range protein ladder was used to confirm the size of protein. Composition 
of 12.5% SDS-PAGE gel is given below: 
 
Table7.  SDS-PAGE gel composition 
Resolving Gel (12.5 %)  Stacking Gel (4 %) 
30% Acrylamide 2.00 ml 30% Acrylamide 0.65 ml 
Tris-HCl, pH 8.8, 1.5M 1.25 ml Tris-HCl,pH 6.8, 0.5M 1.25 ml 
H2O 1.70 ml H2O 3.05 ml 
SDS (10%) 50l SDS (10%) 50l 
TEMED 20l TEMED 10l 
APS 45l APS 25 l 
 
3.12. Expression Analysis of the recombinant clones: E.coli BL21 (DE3) 
pLysS cells transformed with recombinant plasmids were grown and induced for 
protein expression as described by Studier et al [42, 43]. A single colony was 
inoculated in 6 ml of Luria-Bertani medium containing 100g/ml ampicillin and 
grown for 4 hrs at 37
o
C in a screw-cap inoculation vial. From this culture 2ml 
culture was recovered as a reference for uninduced E.coli extract and the 
remaining 4ml culture was induced with 1mM (final concentration) isopropyl--
D-thiogalactopyranoside (IPTG). Following induction the culture was further 
grown for 4 h at 37
o
C and 1.5ml culture was recovered from the induced sample 
as a reference for induced E.coli extract and 750 μl was recovered from 
uninduced culture. The IPTG-induced and uninduced cells were harvested and 
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resuspended in 100l protein extraction buffer (50 mM Tris pH 8.8, 250 mM 
NaCl, 0.05% Triton-X) and lysed by sonication. From the sonicated samples, 
60l were added to 30l of 3x sample loading buffer [18], boiled for 10 min and 
were used for SDS-PAGE analysis in 12% gel. The electrophoresis was carried 
out as mentioned in section 3.11. 
3.13. Purification of His tag UCHL1 protein through Ni
+
-NTA Affinity 
purification: Before protein purification, His-tag proteins were first checked by 
SDS-PAGE for overexpression as described in section 3.12. Purification of N-
terminal His-tag UCHL1 was carried out in one step by affinity purification using 
Ni-NTA chromatography. For this, few colonies of BL21, transformed with 
specific recombinant plasmid DNA, were inoculated into 200 ml LB-broth with 
100μg/ml ampicillin and grown overnight on incubatory shaker at 37oC at 200 
rpm as "pre-inoculum". The grown culture was 10-fold diluted into fresh 2L of 
TB-broth with 100 μg/ml ampicillin. Further incubation was carried out at 37oC at 
200 rpm for 3 hrs, when O.D600 of culture reached to 0.5, the culture was induced 
with 1mM IPTG for 5 hrs at 30
o
C at 200 rpm. Cells were harvested after 
centrifugation at 8000 rpm for 15 minutes at 4
o
C. The cell pellet was suspended 
in 30ml of 50mM Tris-HCl buffer (pH 8.0) containing 300mM sodium chloride, 
0.1% Triton-X, 1mM Imidazole and sonicated on ice for 30 minutes using 
sonicator (Vibra cell, Model No: VCX 130). Sonication program for 2L pellet is 
following; 15sec on, 25% amplitude, and 10 sec off for 25 minutes. The sample 
was then centrifuged at 14,000 rpm for 20 minutes at 4
o
C to remove insoluble 
debris. The soluble fraction was mixed with 2ml of Ni-NTA resin pre-equilibrated 
with the same buffer and allowed to rotate in rotary shaker for 4h at 4
o
C to allow 
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the protein to bind to the resin. The sample was then centrifuged at 1000 g for 5 
minutes at 4
o
C and the washing is carried out in 3 steps with 25ml wash buffer in 
each step (50 mM Tris, pH8.0, 350 mM NaCl, 0.1% Triton-X and 5 mM 
Imidazole). Centrifugation was carried out at 1000g for 4 minutes at 4
o
C. Ni-NTA 
beads bound protein was transferred to poly prep columns (BIORAD). Protein 
was eluted by passing elution buffer (10 mM Tris, pH 8.0, 100 mM NaCl, 400 
mM Imidazole) to the same column. First elute was collected in 1.5 ml of elution 
buffer. Likewise, 4 more elutes were collected. All elutes were checked in 12.5% 
SDS-PAGE. Purification of His tag UCHL1 protein through Ni+-NTA Affinity 
purification:  
3.14. Purification of His tag Ubiquitin protein through Ni
+
-NTA Affinity 
purification: Before protein purification, His-tag proteins were first checked by 
SDS-PAGE for overexpression as described in section 3.12. Purification of C-
terminal His-tag Ubiquitin was carried out in one step by affinity purification 
using Ni-NTA chromatography. For this, few colonies of BL21, transformed with 
specific recombinant plasmid DNA, were inoculated into 200 ml LB-broth with 
100μg/ml ampicillin and grown overnight on incubatory shaker at 37oC at 200 
rpm as "pre-inoculum". The grown culture was 10-fold diluted into fresh 2L TB-
broth with 100 μg/ml ampicillin. Further incubation was carried out at 37oC at 
200 rpm for 3 hrs, when O.D600 of culture reached to 0.5, the culture was induced 
with 1mM IPTG for 5 hours at 30
o
C at 200 rpm. Cells were harvested after 
centrifugation at 8000 rpm for 15 minutes at 4
o
C. The cell pellet was suspended 
in 30ml of 50mM Tris-HCl buffer (pH 8.0) containing 300mM sodium chloride, 
0.1% Triton-X, 1mM Imidazole and sonicated on ice for 30 minutes using 
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sonicator (Vibra cell, Model No: VCX 130). Sonication program from 2L culture 
pellet is following; 15sec on, 30% amplitude, and 10 sec off for 35 minutes. 
Lysate was then centrifuged at 14,000 rpm for 20 minutes at 4
o
C to remove 
insoluble debris. Supernatant (soluble fraction) was collected and heated at 70°C 
for 10mins. Since, ubiquitin is heat stable protein. This step caused denaturation 
of heat unstable soluble proteins of bacteria which on centrifugation at high speed 
of 14000rpm form insoluble aggregate while heat stable soluble proteins remain 
in the scoop and thus reducing the chances of nonspecific contamination of 
purified Ubiquitin. After heating, solution was kept for centrifugation at 14,000 
rpm for 20min. The soluble fraction was mixed with 2ml of Ni-NTA resin pre-
equilibrated with the same buffer and allowed to rotate in rotary shaker for 4h in a 
cold chamber at 4
o
C to allow the protein to bind to the resin. The sample was then 
centrifuged at 1000 g for 5 minutes at 4
o
C and the washing is carried out in 3 
steps with 25ml wash buffer in each step (50 mM Tris, pH8.0, 350 mM NaCl, 
0.1% Triton-X and 5 mM Imidazole). Centrifugation was carried out at 1000g for 
4 minutes at 4
o
C. Ni-NTA beads bound protein was transferred to poly prep 
columns (BIORAD). Protein was eluted by passing elution buffer (10 mM Tris, 
pH 8.0, 100 mM NaCl, 400 mM Imidazole) to the same column. First elute was 
collected in 1.5 ml of elution buffer. Likewise, 4 more elutes were collected. All 
elutes were checked in 12.5% SDS-PAGE.  
3.15. Purification of GST-tag Jab1 Protein: GST tag Jab1 was checked for 
overexpression as mentioned in section 3.11 and purified by GST-glutathione 
affinity purification method. Recombinant plasmid DNA showing over 
expression of recombinant GST fusion protein in expression analysis were 
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transformed into BL21 (DE3) pLysS cells as mentioned in section 3.8(II). 270ml 
LB broth with amp100μg/ml was grown for preinoculum, as described in section 
3.13 and inoculated to 2.7L of TB containing amp of concentration100μg/ml. 
Following induction, cells were pelleted at 8000 rpm, 15min, 4°C. Pellet was 
stored at-86°C. Pellet was resuspended in 10ml of Extraction buffer containing 
the protease inhibitor tablet “cOmplete” (Roche , REF 11836170001).  Dissolved 
pellet was sonicated as described in section 3.13. A 20μl aliquot of cell lysate was 
store at -86°C Cell lysate was centrifuged at 14000 rpm, 20 min at 4°C to separate 
soluble and insoluble fraction. Supernatant was collected in 50ml falcon tube. A 
20μl aliquot of supernatant and insoluble fraction was stored for sds-page analysis 
to identify the presence of fusion protein in the fractions. 800μl of glutathione 
sepharose 4B slurry was added to the supernatant and kept it for binding to at 4°C 
cold chamber on rotary shaker for 2hrs. The the tube was centrifuged at 500g for 
5min at 4°C to sediment the protein bound glutathione matrix. Supernatant was 
collected as flow through (unbound fraction) in a 50 ml falcon tube. A 20μl 
aliquot of flow through was also collected for sds-page analysis. Beads settled on 
the bottom of tube were washed with 10ml wash buffer for 10 min on rotary 
shaker at 4°C and then centrifuge at 500g/4 min/4°C. The supernatant (the 
unbound fraction) was collected by gentle pipetting. Washing step was repeated 
three times. Glutathione beads bound to protein were transferred to 2ml tube. 1.0 
ml of elution buffer (50mM Tris (pH 8.0), 150mM NaCl, 0.05% TritonX, 10mM 
reduced glutathione, 10% glycerol) was added to beads and kept on rotary shaker 
for 25 min. To elute the protein, beads were centrifuged at 500g/5min 4°C and 
supernatant was collected. This process was repeated two more times and total of 
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3 elutions of 1ml each were collected. Aliquot 5μl of each elution was analysed 
by SDS-PAGE, as described in section 3.11. Eluted proteins were stored at -20°C.  
3.16. Establishment of in vitro assay for UCHL1 Activity: Deubiquitinase 
activity of UCHL1 was examined in vitro by using an Ubquitin substrate. 
Ubiquitin with eight amino acids C-terminal extension peptide (Lys-His-His-His-
His-His-His-Cys) was designed as UCH-L1 was reported to cleave the bond 
present between C-terminal glycine of Ubuiqitin and a short peptide, preferably 
starting with lysine. Therefore, the peptide substrate was designed with lysine 
after the last amino acid of Ub (Glycine) followed by six His and a Cys. This 
unique Ub C-terminal extension peptide would help in Ni-NTA purification of 
ubiquitin (Figure 14). The C-terminal eight amino acids (containing the Lys77, 
6x His and Cys83) was added to ubiquitin sequence during cloning using a 
specific PCR primer (Table1: Ub-HindIII-Antisense primer sequence). The in 
vitro assay of UCHL1 deubiquitinating activity on Ubiquitin C-terminal peptide 
substrate was performed by using 15.0M (48g) of UCHL1 and 100M (50g) 
of Ubiquitin in a 50l reaction in 5μl assay buffer. Reaction mix was incubated 
overnight at 30°C. Identical reaction was also carried out with catalytic mutant of 
C90A UCH-L1 as control. Activity of wild type UCH-L1 and the mutant UCH-
L1 on the Ub C-terminal extension peptide was analyzed by gradient SDS PAGE 
gel (4-15%) from BIORAD. 
3.17 In vitro Assay for analysis of Jab1 interaction effect on deubiquitinating 
activity of UCH-L1:  
To examine the effect of Jab1 interaction with UCH-L1 on its deubiquitinating 
activity an in vitro time course and concentration dependent assay were 
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performed. For time course assay, four reactions of final volume 50μl reactions 
were set up. Each reaction contained 20μl (6μg) of Jab1, 5μl of UCHL1 (14.3μg), 
5μl (12.5μg) of Ubiquitin substrate and 5μl of 1X activity assay buffer and 15μl 
of water and incubated at 30°C temperature. Control reactions without Jab1 were 
also set up of final volume 50μl. At each mentioned time point, one of the 
reactions and one of control were taken out and reaction were stopped by adding 
3X –SDS page loading dye and boiled for 10 mins. To examine the JAB1 effect 
on UCH-L1 deubiquitinase activity in concentration dependent manner, we 
gradually increased JAB1 amount. Four reactions were set each having 5μl of 
U8CHL1, 5μl of Ubiquitin and 5μl of 1x activity assay buffer but different 
concentration of JAB1 starting from 0μl,5μl,10μl and 20μl. Final volume of each 
reaction was maintained by water to 50μl. Reactions were incubated for 2hrs at 
30°C.After 2hrs reaction were stopped by adding 3X SDS page loading dye and 
boiled for 10 mins on dry bath. Results were analyzed by SDS page gel 
electrophoresis using pre-casted gradient gels (4-15%).  
3.18. In vitro assay of UCHL-1 with Ubiquitin-AMC:  
UbAMC was dissolved water to make stock solution of final concentration of 100 
M.  UCH-L1 (10nM) and UbAMC (5M) were mixed in reaction buffer (10 
mM Tris•HCl, pH 8.0) was added to initiate the enzymatic reaction (100 μL final 
volume). For Jab1 analysis XXg of Jab1 was added. The rate of AMC cleavage 
was monitored at 25 °C with a Molecular Devices microplate spectrofluorometer 
with excitation at 340 nm and emission at 440 nm.  
3.19   Media and Solutions: De-ionized water was used for all buffers solutions 
and media. 
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3.20   Other solutions: 
Isopropyl β-D-1-thiogalactopyranoside (1M):IPTG 4.7g, H2O 20ml. 
20% SDS: SDS (20g), H2O (80ml). Make final volume 100 ml with stirring. 
Store at room temperature. 
20% Ammonium per Sulphate:  APS (0.2g), H2O (0.8 ml).  
General buffers used in the study: 
           Buffers           Composition 
   TE (Tris-EDTA) 50X 1mM Tris-HCl pH 8.0, 0.1 mM EDTA pH 8.0. A 10X 
stock solution was routinely used to prepare 1X TE. 
SDS-PAGE Resolving gel buffer 1.5 M Tris-HCl, (for Resolving Gel) ,pH 8.8 
SDS -PAGE Stacking gel buffer 0.5 M Tris-HCl (for stacking gel), pH 6.5 
10X SDS-PAGE gel running buffer Tris base 30.3g, Glycine 144g, SDS 10g (add last) , 
makefinal volume to 1000ml. 
1X Gradient gel running buffer 25mM Tris Base, 192mM Glycine, 0.1 % (w/v) SDS, 
methanol 20%. 
3X SDS-PAGE loading dye (10ml) 
 
1M Tris-Cl, pH 6.5 (2.4 ml), 20% SDS (3 ml), Glycerol 
(100%) (3 ml), -mercaptoethanol (1.6 ml), 
Bromophenol blue (0.006g). 
SDS-PAGE staining solution. Coomassie blue R250- 0.4 % w/v, Methanol- 30 % v/v, 
Acetic acid 10 %v/v 
SDS-PAGE destaining solution Methanol- 30 % v/v, Acetic acid 10 %v/v. 
UCHL1 10X assay Buffer 
 
200mM Tris-Cl (pH-8.0), 5mM EDTA, 50mM DTT, 
40% glycerol. 
 
Protein Purification Buffers 
For Ni
+
-NTA purification: 
Extraction Buffer 50 mM Tris (pH 8.0), 300mM NaCl, 0.1% TritonX, 1mM imidazole. 
Wash buffer 50 mM Tris (pH 8.0), 350mM NaCl, 0.1% TritonX, 5mM imidazole. 
Elution Buffer 50 mM Tris (pH 8.0), 100mM NaCl, 0.1% TritonX, 250mM imidazole.  
 
For GST Purification: 
Extraction Buffer 50mM Tris (pH 8.0), 550mM NaCl. 
Wash Buffer 50 mM Tris (pH 7.4), 1M NaCl. 
Elution Buffer 50mM Tris (pH 8.0), 150mM NaCl, 0.05% TritonX, 10mM reduced 
glutathione, 10% glycerol. 
Media Composition 
LB media 1%Tryptone w/v,  0.5% w/v Yeast Extract 
TB media 12g Tryptone , 24 g Yeast Extract 4ml glycerol in 1L 
SOC media 2.0% Tryptone w/v, 0.5 % w/v Yeast extract. 
27 
Figure 1. Restriction analysis of pRSETA-UCHL1 plasmid for 
conformation of positive clones. Lane 1, 1kb Dna Marker; lane 2, pRSETA 
vector; lane 3, NcoI and ScaI digested pRSETA vector; lane 4, pRSETA-
UCHL1; lane 5:NcoI and ScaI digested prsetA-UCHL1. NcoI and ScaI site are 
present within UCH-L1 gene and pRSETA-vector, respectively.Thus, digestion 
with these enzymes release a  fragment of 1200 bp.  
 
 
 
Results and Discussion                                 Chapter  4 
 
4.1. Cloning of human UCHL1: Full length UCH-L1 was PCR amplified using 
pEGFP-C3-hUCHL1 (a generous gift from Kerstin Brinkmann, Kashkar lab 
CECAD, Institute for Medical Microbiology ,Immunoloogy and hygiene 
,Germany) as template and specific primers (UCHL1-BamHI-Sen and UCHL1-
SalI-HindIII-Anti; Table 1). PCR amplification was examined by agarose gel 
electrophoresis and ethidium bromide staining. The expected PCR amplification 
of size 672 bp was observed. The positive clone was identified due to slower 
mobility of the plasmid carrying UCH-L1 DNA to plasmid vector pRSETA.  
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To confirm the presence of UCH-L1 in right orientation, restriction analysis of 
the slow moving clones was performed using enzymes NcoI and ScaI. Insert of 
size 1200 bp confirmed the presence of UCH-L1 gene in correct orientation (Fig. 
1A). A complete plasmid map of pRSET-UCHL1 is shown in Fig 1B. 
4.2. Expression of recombinant human UCHL1 in bacteria. For expression 
analysis pRSET-UCH-L1 plasmid were transformed into E. coli BL21-DE3 
(plysS) strain and checked for over-expression (Fig. 2). Over expression of 
protein was confirmed by visualizing appropriate protein in the total cell extract 
(Fig. 2). 
 
 
 
 
 
 
 
 
4.3. Purification of UCHL1: UCHL1 was expressed as N-terminal His-tag 
fusion protein and purified by Ni
+
-NTA affinity purification.  The samples were 
analyzed on 12.5 % SDS-PAGE (Fig. 3). During purification most of the protein 
was eluted in the first fraction and the yield was 2.8571mg/ml of UCH-L1 as 
analyzed by standard BSA quantification gels (Fig. 7). 
Figure 2. Expression of Recombinant UCHL1 in E. coli. Lane 1:Protein 
molecular wt marker; lane 2, total cell extract; lane 3, IPTG-Induced total cell 
extract showing overexpression of UCHL1 
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Figure 3. Affinity purification of His-tag UCHL1. Lane 1, Molecular wt 
marker; lane 2, total cell extract; lane 3, soluble fraction; lane 4, insoluble 
fraction; lane 5, unbound flow-through fraction; lane 6,  wash fraction; Lane 7-
9, fraction eluted with 250mM imidazole. 
Figure 5. Confirmation of C90A mutation in pRSET-A UCH-L1 by 
sequencing.  
 
 
 
 
 
 
 
 
 
 
4.4. Site directed mutagenesis: To study the enzymatic role of UCH-L1, the key 
residue (Cys90) from catalytic domain were mutated by PCR mediated site 
directed mutagenesis. Cys codon ‘TGT’ was mutated to Ala codon GCT. The 
designed oligonucleotides were complementary to the site of mutation with 19 
nucleotides flanking on both side non-complementary sequences (Table 4). The 
mutation was confirmed by sequence determination (Fig. 5). 
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Figure 6. Affinity purification of His-tag C90A UCHL1. Lane 1, Molecular 
wt marker; lane 2, total cell extract; lane 3, soluble fraction; lane 4, insoluble 
fraction; lane 5, unbound flow-through fraction; lane 6,  wash fraction; Lane 7-
9, fraction eluted with 250mM imidazole. 
4.5. Purification of mutant UCHL1C90A:  UCHL1C90A was expressed as N-
terminal His-tag fusion protein and purified by Ni
+
-NTA affinity purification.  
The samples were analyzed on 12.5 % SDS-PAGE (Fig. 6). During purification 
most of the protein was eluted in the first fraction and the yield was 2.8571mg/ml 
of UCH-L1 as analyzed by standard BSA quantification gels 
 
 
 
 
 
 
 
 
 
 
 
4.6. Cloning of Ubiquitin: Full length human ubiquitin DNA was PCR amplified 
using pET21b-Ubq (produced in own lab) as template and result of amplification 
was examined by 1.0% agarose gel electrophoresis using 1μg/ml ethidium 
bromide to allow visualization of the DNA under UV light. The expected PCR 
amplification of size 204bp was observed. The full length UCHL1 PCR product 
and plasmid pRSETA were sequentially digested by NdeI and BamHI.  Plasmid 
carrying ubiquitin was identified as this moving slower compared to negative 
control (pRSETA) when analyzed on agarose gels. To confirm that the ubiquitin 
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Figure 7: BSA Gel for quantification of  proteins. 
is present in right orientation, restriction digestion was carried out with enzymes 
NdeI and BamHI. The insert release of 204 bp confirmed the presence of UCH-
L1 gene in correct orientation.  
4.7. Expression of Ubiquitin: For expression analysis, pRSET-Ubiquitn plasmid 
were transformed into E. coli BL21-DE3 (plysS) strain and checked for their 
over-expression. When total cell extracts were analyzed by SDS-PAGE, over 
expression of ubiquitin was confirmed (Fig. 8A). 
 
 
 
 
 
 
 
 
 
4.8. Purification of Ubiquitin: Since the ubiquitin constructs has the C-terminal 
His tag, they were purified by Ni-NTA affinity purification. Due to heat-stable 
nature of ubiquitin, total extract was heated and most of the E.coli protein was 
denature except ubiquitin. When the eluted fractions were analyzed on 4-15 % 
gradient gel by SDS-PAGE (Fig 8B), we observed purified ubiquitin protein. 
4.9. In Vitro Assay for UCHL1 Activity: Deubiquitinating activity of UCHL1 
was examined in vitro by using an Ubiquitin substrate. Ubiquitin with eight 
amino acids C-terminal extension peptide (Lys-His-His-His-His-His-His-Cys) 
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was designed as UCH-L1 substrate. UCHL1 mediated peptide cleavage was 
analyzed by gradient SDS PAGE gel (4-15%) from BIORAD. The reaction 
mixture with wild type UCHL1 resulted two bands of the substrate: Ub C-
terminal extension peptide (9.6kDa) and a band of cleaved ubiquitin substrate 
(devoid of peptide extension) of (8.5kDa). As expected, the mutant UCH-L1 
could not cleave Ub C-terminal extension peptide and thus resulted to a single 
band (Fig. 9).  
 
 
 
 
 
 
 
 
4.10. In vitro Assay for UCHL1 Activity with Ub-AMC: UCH-L1 catalyze the 
hydrolysis of ubiquitin-AMC (Ub-AMC, 7-amido-4-methylcoumarin C terminus 
derivative of ubiquitin). Upon formation of the acyl-enzyme intermediate, AMC 
is released from the ubiquitin C-terminus. The free AMC exhibits enhanced 
fluorescence, and the rate of AMC release was monitored by fluorescence 
spectroscopy (em 440nm, ex 340nm). In each reaction, 10nM of UCH- L1 was 
Figure 8. Expression of Recombinant Ub in E. coli. and affinity 
purification of His-tag Ub A. Expression of Ub. Lane 1:Protein molecular wt 
marker; lane 2, total cell extract; lane 3, IPTG-Induced total cell extract 
showing overexpression of Ub. B. Purification of Ub. Lane 1, Molecular wt 
marker; lane 2, total cell extract; lane 3, soluble fraction; lane 4, insoluble 
fraction; lane 5, unbound flow-through fraction; lane 6,  wash fraction; Lane 7-
9, fraction eluted with 250mM imidazole. 
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reacting with 5M of Ub-AMC substrate for 1h. 
4.11. Cloning of JAB1: Full length Jab1 was PCR amplified and the 
amplification was examined by 0.8% agarose gel electrophoresis. The expected 
PCR amplification of size 1005 bp was observed. Plasmid carrying Jab1 DNA 
was moving slower compared to negative control (pGex6p1). To confirm the 
presence of JAB1 in right orientation, restriction analysis of the slow moving 
clones was performed using enzymes BamHI and SalI. The insert release of 1005 
bp confirmed the presence of Jab1 gene in correct orientation.  
4.12. Purification of Jab1: For expression analysis Pgex6p-JAB1 plasmid were 
transformed into E. coli BL21-DE3 (plysS) strain and checked for their over-
expression by SDS-PAGE and coomassie blue staining (Fig. 11). Jab1 was 
expressed as N-terminal GST fusion protein and purified using Glutathione-
sepharose affinity matrix (Fig. 12). Purification yielded .85mg/ml of UCH-L1 in 
Elute1 as analyzed by standard BSA quantification. 
4.13. In Vitro assay to study effect of Jab1 on deubiquitinating activity of 
UCH-L1: As reported in literatures that Jab1 interacts with UCHL1 but the effect 
of this interaction is still unknown. To examine the effect of Jab1 interaction with 
UCH-L1 on its deubiquitinating activity, in vitro assay were performed. We 
added 14.3 μg (5μl) of UCHL1, 12.5μg of Ubiquitin with 6μg (20μl) of Jab1 and 
5μl of 1X assay buffer. Total reaction volume was made 50μl and incubated the 
reaction at 30C in the presence of for 8h. Control reactions without Jab1 were 
also set up simultaneously. At 2, 4, and 8h, 50μl aliquots from this reaction and 
control were taken out and stopped by adding SDS page loading dye and boiled 
for 10 minutes and analyzed by SDS-PAGE gel electrophoresis. As shown in Fig. 
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Figure 10. Expression of Recombinant Jab1 in E. coli. Lane 1:Protein 
molecular wt marker; lane 2, total cell extract; lane 3, IPTG-Induced total cell 
extract showing overexpression of UCHL1 
Figure 9. UCHL1 assay using Ub-C-terminal peptide as substrate. Ub-C-
terminal substrate was incubated with UCH-L1 and analyzed by SDS-PAGE. 
Lane 1 and 3, Ub--C-terminal substrate without UCH-L1; lane 2, UCH-L1 
with Ub substrate; lane 4,  C90A UCHL1 with Ub-C-terminal substrate; lane 5, 
protein Mw marker. Arrows indicate the position of the cleaved substrate. 
13, at 0h there was no substrate cleavage, as no band of cleaved peptide was 
observed on the gel. Interestingly, at all the time points, especially at 2h time 
point, it was observed that reaction without Jab1 had more cleavage compared to 
the reaction with Jab1 (Fig. 13). These results suggest that presence of Jab1 
prevents UCH-L1 protease activity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
35 
Figure 13. Cleavage activity of recombinant UCHL-1 protein is regulated by 
Jab1. Purified GST-UCHL1 was incubated with Ub substrate in presence (lanes 
1-4) and absence (lanes 6-9) of Jab1. Samples were analyzed after 2, 4 and 8 hours 
to detect cleavage of Ub substrate; lane 5, molecular weight markers. The position 
of cleaved  proteins are shown by arrows. 
Figure 11. Affinity purification of GST-tag Jab1. Lane 1:Protein molecular 
wt marker; lane 2, total cell extract; lane 3; soluble fraction; lane 4, Insoluble 
fraction Lane 5, unbound flowthrough fraction; lane 6 wash fraction; lane 7-9, 
elution fractions 
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Figure 14. Effect of Jab1 on ubiquitin-AMC cleavage by UCHL1. Ubiquitin-
AMC (5μM) was incubated with wild-type UCHL1 or UCHL1 and Jab1. Cleavage 
of ubiquitin-AMC was measured after 1h by fluorescence (340 nm excitation/440 
nm emission). 
4.14. In Vitro Ub-AMC assay to study effect of Jab1 on deubiquitinating 
activity of UCH-L1: When Jab1 (18g; 2.7nM) was incubated with UCHL1 
(10nM) in presence of 5M of Ub-AMC, it clearly inhibited AMC release, 
suggesting inhibitory role of Jab1 (Fig14). Together, these results suggest that 
UCHL1 deubiquitinating activity on our designed ubiquitin C-terminal extension 
peptide substrate and also on Ub-AMC substrate is transiently inhibited by the 
presence of JAB1. The plausible explanation of such transient inhibition effect 
can be the location of Jab1 binding region on UCHL1. The Jab1 interaction motif 
is present on UCHL1 at a loop3 which is also covers residues present in Ubiquitin 
binding domain (P-site) of  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
37 
 
UCHL1. Since structure of UCHL1 shows that it undergoes a conformational 
change upon binding of substrate and then become catalytically active it is 
possible that slight coverage of ubiquitin binding site by Jab1 binding is resisting 
UCHL1 to undergo the required conformational change to make it catalytically 
efficient. It might be also possible that such transient interaction of JAB1 to 
UCHL1 is promoting Jab1 mediated phosphorylation or any other post 
transcriptional modification in UCHL1 since Jab1 is known to have kinase 
activity associated with it. Or, it is also possible that binding of Jab1 inducing 
some conformational change in UCHL1 and thus Jab1 cannot interact further with 
UCHL1. Indeed further studies are needed to solve the enigma of transient 
inhibitory effect of JAB1 interaction on UCHL1 which will allow to better 
understanding of UCHL1 role in signaling pathways and will also be very helpful 
to understand the regulation of UCHL1 activity inside the cell. 
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